Micafungin Hikma (Micafungin)

Micafungin Hikma is an echinocandin antifungal used to manage serious Candida infections and prevent them in vulnerable patient groups.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in immunocompromised patients.
• Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida species.
• Prophylaxis in hematopoietic stem cell transplant recipients: prevents Candida infection during the high‑risk post‑transplant period.
• Candida peritonitis and intra‑abdominal infections: treats severe intra‑abdominal Candida infections when systemic therapy is required.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug compromises fungal integrity, leading to cell lysis and eradication of susceptible Candida species.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate headache.
• Elevated liver enzymes: mild, reversible increase in hepatic transaminases.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury requiring monitoring.
• Hypersensitivity reactions: rash, pruritus, or anaphylaxis.
• Severe infusion‑related reactions: hypotension or bronchospasm during administration.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.

• Liver function: obtain baseline hepatic enzymes and monitor periodically.
• Renal function: evaluate kidney status, especially in patients with concurrent nephrotoxic agents.
• Concomitant antifungals: avoid overlapping therapy with other echinocandins.
• Pregnancy and lactation: use only if benefit outweighs potential risk; category B.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Cyclosporine: increased cyclosporine exposure may raise nephrotoxicity risk.
• Rifampin: may reduce micafungin plasma concentrations, compromising efficacy.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity.
• Immunosuppressants (e.g., tacrolimus): monitor drug levels for possible changes.
• Warfarin: observe INR for any unexpected shifts.